An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.72% to $416.96 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.21 ...

Get Pro-Level Earnings Insights Before the Market Moves In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc VRTX, defending its ...

NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ ...

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...

Shares of Vertex Pharmaceuticals Inc. VRTX advanced 3.06% to $424.26 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising ...

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX ...

If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as income from Casgevy remains low in the near term, helping to diversify its ...